SARS-CoV Infection Clinical Trial
Official title:
Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study
Remdesivir is a monophosphoramidate prodrug of an adenosine analogue and it has a
broad-spectrum antiviral activity against paramyxoviruses, falviviruses and coronaviruses. It
showed in vitro activity on human airway epithelial cells against SARS-CoV-2. It is an
investigational drug and granted an Emergency Use Authorization by Food and Drug
Administration FDA, so it is under clinical trial.
The potent mechanism of action of this drug is still unclear but it effects through several
processes. It can interfere with nsp12 polymerase even when exoribonuclease proofreading is
intact. It can also produce nucleoside triphosphate NTP that acts pharmacologically active
alternate substrate of RNA-chain terminator, as a result NTP can constrain active
triphosphates into viral RNA of coronaviruses. There is evidence of high genetic barrier to
develop resistance against Remdesivir in coronavirus as a result of which is maintains its
effectiveness in antiviral therapies against these viruses. Effectiveness of Remdesivir has
been reported against different groups of coronaviruses including Alphacoronavirus NL63 and
several SARS/MERS-CoV coronaviruses.
This is interventional single-center study, that will be done at Lahore General Hospital in
which 95 beds are allocated for COVID-19 patients including ICUs and HDUs. Ethical approval
will be obtained from research ethical committee of Lahore General hospital, Lahore. Informed
consent will be obtained from all patients who will agree to publish their data in this
research. Patient's privacy protection will be obeyed with the Helsinki Declaration.
The aim of this study is to evaluate clinical effectiveness of this investigational drug,
started a clinical trial of this drug on laboratory-confirmed COVID-19 patients at a tertiary
care hospital of Lahore, Pakistan.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546776 -
COVID-19 Persistence in Stool
|
||
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
| Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
| Recruiting |
NCT04615052 -
Home-based Exercise in COVID-19 Survivors
|
N/A | |
| Enrolling by invitation |
NCT04659486 -
Adolescents With COVID-19/MIS-C at HCFMUSP
|
N/A | |
| Recruiting |
NCT04885452 -
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
|
||
| Completed |
NCT04516928 -
Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
|
||
| Completed |
NCT05063812 -
Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
|
||
| Completed |
NCT04530357 -
Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04565782 -
Corona Virus Infection Among Liver Transplant Recipients
|
||
| Completed |
NCT04550390 -
Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
|
||
| Completed |
NCT04733625 -
The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection
|
N/A | |
| Active, not recruiting |
NCT04517136 -
Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
|
||
| Recruiting |
NCT04476680 -
Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion
|
N/A | |
| Completed |
NCT04839913 -
Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
|
||
| Completed |
NCT04514874 -
Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
|
||
| Terminated |
NCT04606563 -
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
|
Phase 3 | |
| Completed |
NCT05234359 -
The CHILD Cohort COVID-19 Add-On Study
|